Dr. John Harper, Senior Medical Scientist at 3M Healthcare, joins Board at Kent Imaging

January 27, 2020. Kent Imaging announced today the addition of Dr. John Harper, Ph.D. to its Board of Directors and welcomes him as an investor in the organization. His addition to the board complements and strengthens its existing directors’ expertise in business, medicine and marketing by adding advanced product strategies and strong industry connections. 

“We are extraordinarily pleased with the addition of Dr. Harper to the Board of Directors and are honored to have him on the team” comments Don Chapman, Founder and Chairman of the Board at Kent Imaging. “He will contribute a wealth of knowledge, strategic insight, medical product development and commercialization experience to the Board.”

Dr. Harper brings over 35 years of research and healthcare industry experience to the table.  During his tenure at LifeCell, Dr. Harper oversaw the development of pivotal scientific and clinical data proving the utility of its regenerative products AlloDerm, Strattice, and GraftJacket.  He also led the introduction of Novadaq and SPY Elite technology to LifeCell for launching into the plastic surgery space. Currently, Dr. Harper is a Senior Medical Scientist at 3M – Medical Solutions Division, providing leadership over the company’s global technology and innovation outreach, as well as product portfolio strategy and execution. Prior to 3M’s recent acquisition of KCI, Dr. Harper led KCI’s Center for Advanced Research and Technology, as well served as Senior Vice President for Global Clinical and Regulatory Affairs.  Most recently as Chief Technology Officer at KCI, Dr. Harper was responsible for early stage innovation and technology development.  Dr. Harper received his Ph.D. in Biomedical Sciences from The University of Texas, M.D. Anderson Cancer Center in Houston and completed post-doctoral fellowships in cancer biochemistry and cell biology at Scripps Clinic in La Jolla, CA and the National Cancer Institute in Bethesda, MD. 

“I am joining Kent’s Board at a time when the need for advancing new technologies in all aspects of surgery and wound care at a cost-effective price point is critical. A number of years back, I took an interest in the imaging technology developed by the company, and am impressed by the progress to date and the direction Kent is taking. I am excited and honored to join the Board and this will provide me with the opportunity to lend my experience and expertise to further enhance growth of the organization” states Dr. Harper.

About Kent Imaging Inc.

Kent Imaging, located in Calgary, Alberta, Canada, is a leading developer of medical technology, who designs, manufactures and markets near infrared imaging technology for wound and surgical care. Kent holds multiple patents in medical technology and continues to provide innovative and advanced diagnostic imaging solutions to aid healthcare systems nationally and internationally. For more information about Kent Imaging, visit www.kentimaging.com.

Advancing Tissue Assessment: SnapshotNIR imaging similar to ICG fluorescence angiography

A new study published by Jones, G. et al. in Plastic and Reconstructive Surgery (PRS) January 2020 highlights the comparable accuracy between SnapshotNIR and ICG fluorescence angiography in assessing flap outcome in the immediate post-operative period. The article “Snapshot Multispectral Imaging Is Not Inferior to SPY Laser Fluorescence Imaging When Predicting Murine Flap Necrosis” shares results that are extremely encouraging for the use of SnapshotNIR intraoperatively in flaps in a timely and non-invasive manner. https://journals.lww.com/plasreconsurg/Abstract/2020/01000/Snapshot_Multispectral_Imaging_Is_Not_Inferior_to.29.aspx